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INFANT POPULATIONS EXPOSED TO PROLONGED SEDATION:  
ARE THEY AT RISK FOR LONG-TERM SEQUELAE? 
 
COLLEEN ANDREWS 
 
 
ABSTRACT 
Objective: Opioids are considered standard of care for pain treatment for infants 
undergoing painful procedures. In addition, prolonged opioid administration is 
used for sedation during non-surgical treatment (e.g. infants that require 
intubation and prolonged ventilation).  Intubated infants often receive sedative 
drugs for a prolonged period of time, which leads to opioid dependence and 
tolerance. The long-term sequelae of such treatment involving the prolonged 
administration of opioids are unknown.  There is evidence in cell cultures and 
animal models that prolonged opioid exposure is associated with increased 
neuronal apoptosis (neuronal cell death).  In addition, human studies in 
premature children have suggested that prolonged opioid treatment is associated 
with decreased visual intelligence, social skills, and memory function.  The goal 
of this study was to identify the population of the youngest patients (less than one 
year old) that requires prolonged administration of opioids for pain and sedation 
management.  Our overarching hypothesis is that a select group of patients 
might be at risk for long-term neurologic sequelae from prolonged opioid 
treatment.   
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Methods: A retrospective chart review for admission cases over a period of one 
year was conducted to identify infants that received prolonged administration of 
opioids and/or benzodiazepines for their treatment.  Infants were included if they 
were less than one year old, full-term (born 37-42 weeks of gestational age), and 
received prolonged treatment with opioids (e.g. fentanyl, morphine, 
hydromorphone) and/or benzodiazepines (e.g. midazolam, diazepam, 
lorazepam).  Data on their diagnoses and sedation management at Boston 
Children’s Hospital, including total dose of drugs received and if they developed 
dependence, was collected.  
 
Results: Out of the 221 charts reviewed, only 46 infants were exposed to 
prolonged sedation and were full-term.  Of these 46 infants, the largest 
proportion (35%; 16/46) was diagnosed with congenital anomalies.  The other 
diagnoses included respiratory diseases (24%; 11/46), neurological diseases 
(13%; 6/46), and the remaining infants had a combination of two to three of these 
diagnoses (28%; 13/46).  Infants with congenital diseases had a longer duration 
of sedation management (59.3 days ± 31.3 days) than infants with respiratory 
distress/infection (5.9 days ± 3.4 days).  Those receiving the longest opioid 
treatments also exhibited signs of withdrawal when drugs were discontinued, 
which suggested the development of opioid dependence and required weaning 
treatment.  Patients with sedation for 4 days or less did not show withdrawal 
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symptoms, while those with sedation of 6 days or more required an opioid and 
benzodiazepine weaning regimen.  
 
Conclusion: The chart review was valuable from several perspectives. Sedation 
management at Boston Children’s Hospital included prolonged administration not 
only of opioids, but also benzodiazepines.  Such treatment is considered the 
standard of care.  Even otherwise healthy, full-term children that received such 
sedation for the management of an acute illness (e.g. pneumonia) were at risk for 
opioid and benzodiazepine dependence if they required intubation and sedation 
for longer than 4 days.  However, the majority of full-term children at risk for 
potential long-term sequelae of prolonged sedation presented with other 
confounding factors (e.g. congenital diseases, surgeries, exposure to anesthetic 
agents).  In summary, future research on potential long-term sequelae of 
prolonged opioid administration should include infants with complex medical 
diseases as they were exposed to such treatment the longest.  
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INTRODUCTION 
It was not until the 1990s that administration of prolonged opioids and 
benzodiazepines was considered standard of care for sedation of ventilated 
infants (Hall, 2009).  Prior to this, pain medicine was not administered to the 
youngest patients under the assumption that infants did not feel pain (Hall, 2009).  
However, a study by Anand, Hansen, & Hickey (1990) suggested that infants do 
feel pain and actually have higher stress responses than adults while 
experiencing pain (e.g. while undergoing surgery).  In order to quantify the 
infants’ stress responses, Anand et al. (1990) measured several hormonal and 
metabolic stress markers, including cortisol and epinephrine, during the 
perioperative period for surgery.  Figure 1 illustrates the increase in stress 
indicators during and after surgery (Anand et al. 1990).  Surgery was associated 
with a significant increase in stress markers (plasma epinephrine, 
norepinephrine, insulin, and glucagon) indicating that infants do feel pain.  In 
addition, the infants that died during the study had higher levels of stress 
indicators than those that survived.  Given this association, decreasing stress 
indicators may improve survival rates (Anand et al.,1990).  
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In addition to the evidence that untreated pain is associated with perioperative 
stress, untreated pain is also associated with increases in “heart rate, respiratory 
rate, intracranial pressure, blood pressure” (Bellù, Waal, & Zanini, 2010) and 
potential decreases in oxygen saturation that may contribute to the “development 
of complications such as intraventricular haemorrhage” (Bellù et al., 2010).  Pain 
can also diminish the effectiveness of intubation by disrupting ventilation and 
breathing patterns (Bellù et al., 2010).  We now know that chronic untreated pain 
in infants interferes with an infant’s developing nervous system (Walker, 2013) 
and is associated with long-term neurologic sequelae.  As a result, opioids (e.g. 
 
Figure 1: Perioperative Stress Response in Neonates. Stress biomarkers for 15 infants 
with congenital heart diseases were measured during the perioperative period.  Data on 
plasma epinephrine, plasma norepinephrine, plasma insulin, and plasma glucagon were 
collected.  Figure taken from Anand et al., 1990. 
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morphine, fentanyl, hydromorphone) and benzodiazepines (e.g. midazolam, 
diazepam, lorazepam) have become the standard of care for infants undergoing 
painful procedures and prolonged sedation (Anand et al., 2010).  The World 
Health Organization currently recommends the use of opioids for infants with 
moderate to severe pain (WHO, 2012).  
 
Pain Pathways in Newborns and Infants 
Research over the last 20 years has elucidated differences in pain processing 
between the developing and adult brain.  Since the infant nervous system is still 
developing and undergoing significant changes, there are important differences 
between pain pathways in young children and adults (Fitzgerald 2005; Baccei & 
Fitzgerald, 2005).  Based on studies in rat models, developing nervous systems 
are unique because of intersection between the A-fiber terminals and the C-fiber 
terminals in the dorsal horn (Figure 2-2) (Beggs, Torsney, Drew, & Fitzgerald, 
2002; Granmo, Petersson, & Schouenborg, 2008; Fitzgerald & Walker, 2009).  
Eventually the infant’s nervous system matures and these areas become distinct 
regions; however, while they still intersect, it is difficult for the developing nervous 
system to differentiate painful inputs from non-painful ones (Fitzgerald & Walker, 
2009).  Without a well-developed neuronal network, newborns cannot integrate 
inputs from painful stimuli effectively, resulting in more dispersed pain than in 
adults (Figure 2-3) (Fitzgerald & Walker, 2009).  Primary hyperalgesia occurs 
when the area surrounding an injury causes pain (Woolf, 2007), while secondary 
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hyperalgesia is characterized by pain occurring outside the initial site of injury 
(Walker, 2009).  While neonates experience primary hyperalgesia like adults 
(Andrews & Fitzgerald, 2002; Torsney & Fitzgerald, 2002; Ririe, Vernon, Tobin, & 
Eisenach, 2003), secondary analgesia is not present to the same extent as in 
mature nervous systems (Figure 2-4) (Walker, Meredith-Middleton, Lickiss, 
Moss, & Fitzgerald, 2007).  Furthermore, the neonatal nervous system is 
characterized by undeveloped descending pain modulatory pathways (Figure 2-
5), an immature cortex,  (Figure 2-6), and somatosensory responsiveness to 
painful stimuli (Figure 2-7) (Fitzgerald & Walker, 2009).  
 
 
Figure 2: A Summary of the Neonatal Pain Pathway. There are several important 
differences between pain pathways in adults and neonates.  In the neonatal dorsal horn, 
there is overlap between the C-fibers and the A-fibers, leading to more dispersed pain.  
Figure taken from Fitzgerald & Walker, 2009. 
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Importance of Pain Management 
In addition to the short-term effects of anesthesia, there are also long-term 
benefits of opioid therapy compared to infants not receiving pain management. 
Several studies have compared premature neonates receiving opioids to control 
groups not receiving opioid treatment.  In a prospective cohort study by Grunau, 
Oberlander, Witfield, Fitzgerald, & Lee (2001), low birth weight infants underwent 
a heel stick at 32 weeks after birth to determine their reaction to pain.  Compared 
to infants who did not previously receive morphine, those who had previously 
received morphine had an improved pain response (Grunau et al., 2001).  
 
In addition to the beneficial effects of pain treatment in acute settings, prolonged 
administration of opioids has shown to have beneficial effects as well.  
Specifically, MacGregor, Evans, Sugden, Gaussen, & Levene (1998) analyzed 
infants who required ventilation and were randomized to morphine or non-
morphine solution.  At 5-6 years of age, the children were assessed using the 
Movement Assessment Battery for Children, the Child Behaviour Checklist, and 
the Weschler Preschool and Primary Scale of Intelligence.  While the results 
were not significant, children who received morphine as infants tended to do 
better on the scales than those who were ventilated but did not receive morphine 
(MacGregor et al., 1998).  Another study by Anand et al. (1999) reported that 
children treated with morphine had the least number of neurological 
complications (e.g. intraventricular hemorrhage and periventricular leukomalacia) 
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compared with placebo- and midazolam-exposed infants.  These neurological 
outcomes occurred in 32% of the midazolam-treated infants, 24% of the placebo 
infants, and 4% of the morphine-exposed infants (Anand et al., 1999).  Anand et 
al. (1999) concluded that compared to placebo, morphine infusion may decrease 
the incidence of neurological outcomes in mechanically ventilated premature 
neonates.  These results suggest that treatment of neonatal pain is essential to 
normalize pain responses and protect neurological development.  
 
Opioid Analgesic Mechanism 
Non-opioid analgesics like sucrose can improve behavioral reactions to pain, but 
these medications do not hyperpolarize neurons to reduce painful sensations 
(Walker, 2013).  In contrast, the administration of opioids is considered effective 
pain management, as opioids are useful agents to provide effective prolonged 
sedation in infants (Suresh & Anand, 2001).  Opioids bind –µ, –δ, and –κ opioid 
receptors found in several areas of the nervous system, including the spinal cord, 
brain, peripheral nociceptors, and the myentric plexus.  These receptors also 
occur on cells such as skeletal and cardiac muscle cells, monocytes, and 
lymphocytes (Suresh & Anand, 2001).  When morphine or other opioids bind 
these receptors, a signal cascade is activated that leads to hyperpolarization of 
the neurons (Suresh & Anand, 2001).  Specifically, binding of an opioid to an 
opioid receptor causes the receptor to undergo conformational changes.  These 
changes activate the inhibitory G-proteins G0 and Giα, which affect nitric oxide 
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synthetase and potassium channels and decrease adenylyl cyclase activity, 
respectively.  Through these effects, the neuron becomes hyperpolarized, raising 
the threshold necessary to depolarize the neuron and propagate an action 
potential (Figure 3).  In addition, the amount of neurotransmitter released and 
the action potential length are reduced.  Ultimately, these changes decrease 
neuronal firing, producing analgesia and sedation (Suresh & Anand, 2001). 
 
 
 
 
 
  
	     8 
 
Figure 3: Mechanism of Opioid Analgesia. An opioid binds an opioid receptor, which leads to a 
signal cascade producing analgesia and sedation.  Figure taken from Anand et al., 2010.   
 
Neurological Effects in Animal Models 
Apoptosis, or programmed cell death, occurs as a normal part of development for 
the pruning of neuronal connections.  Exposure to opioids, such as morphine and 
fentanyl, may enhance physiologic apoptosis.  Both in vitro and in vivo models 
indicate that prolonged opioids are associated with increased apoptosis.  Infants 
are especially susceptible to neurological deficits since their nervous systems are 
undergoing significant changes.  Specifically, normal brain development is 
characterized by overproduction of neurons and subsequent neuronal pruning 
(Buss & Openheim, 2004).  While this programmed cell death, or apoptosis, is a 
Opioid Analgesia
Binding of specific ligands to opioid
receptors lead to conformational
changes in the receptor protein that
initiate signal transduction with the
activation of inhibitory G proteins (Gi2!
and Go). Activation of Gi protein down-
regulates adenylate cyclase (AC), thus
reducing intracellular cyclic adeno-
sine monophosphate (cAMP) levels,
whereas Go proteins regulate an inter-
nally rectifying K! channel to cause hy-
perpolarization of the neuronal mem-
brane.42 Signal transduction from
activated opioid receptors lowers neu-
ronal excitability, reduces action-
potential duration, and decreases neu-
rotransmitter release, which leads to
opioid analgesia (Fig 1).
Opio d-Induced Hyperalgesia
Some opioid agonists elicit naloxone-
reversib e and dose-dependent excita-
tory effects at the opioid receptor.10,43
These effects result from opioid recep-
tors coupling with stimulatory G pro-
teins (Gs), which stimulate AC, increas-
ing cAMP and activating protein kinase A
and ultimately leading to neuronal acti-
vation.44 Neuraminidase increases these
effects, whereas treatment with a neur-
aminidase inhibitor (eg, oseltamivir)
blocks the “paradoxical” hyperalgesia
caused by opioid therapy.45
Opioid-induced hyperalgesia occurs
even in the absence of opioid toler-
ance (Fig 2), as demonstrated in opi-
oid addicts, normal adult volunteers,
and those who receive opioid ther-
apy with morphine, fentanyl,
remifentanil, hydrocodone, oxyc-
odone, or methadone.46 Finkel et al47
postulated its occurrence in children
with intractable cancer pain and suc-
cessfully treated them with low-dose
infusi ns of ketamine. Propo ed
mechanisms include the sensitization
of primary afferent neurons, enhanced
production and release of excitatory
neurotransmitters, decreased re-
uptake of excitatory neurotransmit-
ters, sensitization of second-order
neurons, and descending facilitation
from the rostral ventromedial medulla
associated with upregulation of the
central dynorphin and glutamatergic
systems.46,48,49
K channel  
+ 
µ-Opioid agonist 
Adjacent neurons  
µ-OR 
PLA 2 
AC 
cAMP 
NO 
cGMP 
nNOS 
PKC 12-lipoxygenase 
12-HPETE 
Arachidonic 
acid 
G i 
G o 
+ 
+ 
Glutamate- 
binding site 
threshold, 
Analgesia cascade: 
APD, 
neurotransmitter  
release 
Ca 2+
Ca 2+ 
Mg 2+
NMDA receptor
FIGURE 1
Diagrammatic representation of the neuronal mechanisms underlying opioid analgesia. Mechanisms that support the analgesia cascade increase resting
membrane potential, reduce action potential duration, and decrease neurotransmitter release. "-OR indicates "-opioid receptor; Gi/Go, inhibitory G
proteins; nNOS, neuronal nitric oxide synthetase; NO, nitric oxide; cGMP, cyclic guanosine monophosphate; PLA2, phospholipase A2; APD, action potential
duration; HPETE, hydroperoxyeicosatetraenoic acid.
REVIEW ARTICLES
PEDIATRICS Volume 125, Number 5, May 2010 e1211 at Harvard University on September 4, 2012pediatrics.aappublications.orgDownloaded from 
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necessary part of healthy brain development, external stimuli can also affect this 
natural process (Blaschke, Staley, & Chun, 2004; Rabinowicz, de Courten-
Meyers, Petetot, Xi, & de los Reyes, 1996; Raff et al., 1993; Rakic & Zecevic, 
2000).  In rat models, stimuli that interfere with natural apoptosis are associated 
with neurological damage and even death (Kuida et al., 1996).  Specifically, 
Goswami, Dawson, & Dawson (1998) concluded that opioids kill cells through 
apoptosis by blocking adenylate cyclase in cell culture.  An animal study by 
Emeterio, Tramullas, & Hurlé (2006) found that chronic, but not acute, morphine 
leads to increased number of apoptotic cells in glial cells and neurons throughout 
the brain.  A study by Mao, Sung, Ji, & Lim (2002) reported increased apoptosis 
in the adult rat spinal cord after prolonged administration of morphine associated 
with the development of opioid tolerance.  Furthermore, a study by Bajic, 
Commons, & Soriano (2013) reported that prolonged administration of morphine 
associated with the development of opioid tolerance leads to increased apoptosis 
within selected brain regions of developing rat brain: the somatosensory cortex 
and amygdala (Figure 4). 
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Figure 4: Density of Apoptotic Cells at Postnatal Day 7 in an Infant Rat Model.  
Three groups of infant rats were analyzed at post-natal day seven (PD7): the naïve group did not 
received any treatment (n=6), the saline group received saline twice daily for 7 days (n=5), and 
the morphine group received morphine twice daily for 7 days (n=8). The number of apoptotic cells 
(caspase-3 immunoreactive cells) was analyzed in different brain regions known to be involved in 
opioid effects. There is a significant increase in the number of apoptotic cells in the cortex and the 
amygdala, but not the hippocampus, hypothalamus, or periaqueductal gray (PAG).  Figure taken 
from Bajic et al., 2013. 
 
Increased apoptosis in the amygdala and cortex is especially important because 
these are the areas of the brain involved in opioid processing (Veinante, Yalcin, 
& Barrot, 2013; Casey et al., 2000).  The cortex is involved in somatosensory 
processing as part of pain pathways (Bushnell et al., 1999), while the amygdala 
is involved in the emotional-affective dimension of pain, addiction, and possibly in 
drug-associated memory and drug seeking behavior (Veinante et al., 2013; 
Koob, 2003; Kruzich & See, 2001).  All together, compelling research evidence 
Author's personal copy
D. Bajic et al. / Int. J. Devl Neuroscience 31 (2013) 258–266 261
Fig. 2. Anatomical regions of analysis in PD7 rats. Representative coronal forebrain (A) and brainstem (B) sections of newborn rat at the postnatal day (PD) 7 schematically
illustrate anatomical regions of interest. Sections were drawn from a representative animal that was treated with morphine for 6½ days. Solid lines outline the brain
sections, while dashed lines illustrate approximate location of anatomical landmarks. Dots illustrate distribution of caspase-3 immunoreactive cells. Density of caspase-3
immunoreactive cells was  analyzed in anatomical regions shown in gray. These areas include: (1) cortex, (2) hippocampus (Hipp), (3) amygdala (Amyg), (4) hypothalamus
(Hypoth),  and (5) periaqueductal gray of the midbrain. Region of cortex included visual cortex (VCtx), somatosensory cortex (SCtx), auditory (AuCtx) and piriform (Pir)
cortex at the level of the thalamus (Th). Hypothalamus included both posterior hypothalamic area (PH) and ventromedial hypothalamic nucleus (VMH). Periaqueductal gray
included both of its divisions: ventrolateral (vlPAG) and dorsolateral (dlPAG).
Source: Abbreviations were adapted from The Rat Brain Atlas (Paxinos and Watson, 1998).
3.3. Cell type of caspase-3 immunoreactive cells: double-labeling
immunofluorescence
3.3.1. Neuronal apoptosis
Caspase-3 immunoreactive cells exhibited morphology anal-
ogous to different neuronal cell types. In the cortex, caspase-3
immunoreactive cells were typically located in the superficial gran-
ular layer (Layer 2) (Vernon, 1998) and corresponded to smaller
pyramidal neurons. Caspase-3 immunoreactive cells of the internal
pyramidal layer (Layer 5) (Vernon, 1998) exhibited morphology of
large neurons. Caspase-3 immunoreactive cells in the cortical mul-
tiform layer (Layer 6) (Vernon, 1998) and hippocampus exhibited
morphology of stellate or basket neurons. The neuronal nature of
Fig. 3. Density of caspase-3 immunoreactive cells in newborn rat at PD7. Graph
illustrates average density of apoptotic cells (#caspase-3 cells/section/brain) ± SD
among three treatment groups (naïve, normal saline (control), and morphine (tol-
erant) group) in five different anatomical regions of interest. There are no differences
in  density between naïve and control groups in any of the regions analyzed. Mor-
phine treatment was  associated with increased density of apoptotic cells only in the
cortex (F(2,15) = 5.82; p = 0.013) and amygdala (F(2,13) = 5.84; p = 0.006) of newborn
rats. Pairwise comparisons of all groups showed statistically significant increase
in  density of caspase-3 immunoreactive cells in tolerant group compared to naïve
(p  < 0.05) and control groups (p < 0.05 for cortex; p < 0.01 for amygdala). We found
no statistical difference in density of apoptotic cells in hippocampus (F(2,13) = 0.47;
p  = 0.63), hypothalamus (F(2,10) = 1.68; p = 0.23), and periaqueductal gray (PAG;
F(2,12) = 0.34; p = 0.71) among different treatments. For schematic representation
of  anatomical regions of analysis, refer t  Fig. 2. One-way ANOVA with Tukey post
hoc  test. Asterisks (*) denote statistically significant increase in values.
caspase-3 immunoreactive cells was confirmed by double-labeling
immunofluorescence for neuronal nuclear stain (NeuN; Fig. 4A), as
well as nNOS (Fig. 4B). Since the density of apoptotic nNOS neurons
was small (0–3 double-labeled neuron/section/brain) in each treat-
ment group, no quantitative analysis was done. In addition, clusters
of caspase-3 immunoreactive cells without a defined morphology
were also double labeled with nNOS (Fig. 5A; see below for details
on caspase-3 immunoreactive clusters). Since it is a specific neu-
ronal marker, nNOS cells did not co-localized with any of the glial
labeling.
3.3.2. Glial apoptosis
Few microglial cells (0–2 double-labeled microglial
cells/section/brain) were double-labeled with caspase-3 and
Iba-1 immunohistochemistry in each treatment group (Fig. 4C). In
addition, the specific marker of microglia used in this study (Iba-1)
failed to detect activation of microglia in any of the treatment
groups. In other words, there was no difference in morphological
appearance of Iba-1 labeled microglia between the treatment
groups in any of the regions analyzed (not shown). Further-
more, we did not identify any isolated GFAP-immunoreactive
astrocytes that were double-labeled with caspase-3 throughout
the forebrain or midbrain in any of the treatment groups. In
addition, morphological characteristics of GFAP-immunoreactive
astrocytes did not differ between the treatments in any of the
regions analyzed (not shown). One exception was the presence of
caspase-3 immunoreactive cells in sparce clusters that were losing
their morphological features. Clusters were noted to be double-
labeled with GFAP, while GFAP labeling showed characteristics of
astrocytic activation, such as cellular hypertrophy (Fig. 5B). These
sparse clusters of caspase-3 immunoreactive cells were found
only in the cortex and hippocampus of the morphine group. Since
the density of identified caspase-3 immunoreactive clusters were
small (0–3/tolerant brain), no quantitative analysis was done.
4. Discussion
In the present study, we used previously published model of
morphine dependence and antinociceptive tolerance in newborn
rats (Barr and Wang, 1992; Jones and Barr, 1995; Zhu and Barr,
2003). The latter was also confirmed in our recent report (Bajic
et al., 2012). Our current findings demonstrate that prolonged mor-
phine administration in the neonatal rat (PD1–7) is associated with
an increased density of apoptotic cells in selected brain regions.
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suggests that neuronal adaptations might be associated with long-term 
behavioral and neurologic sequelae.  
 
Translation of Animal to Human Research  
The evidence on prolonged opioid exposure in animals is concerning for 
prolonged opioid treatment in human infants.  Because there are common 
features of animal and human neurobiology, there are certain shared factors that 
can affect whether both animals and humans have long-term sequelae from 
prolonged opioid exposure.  Age, length of exposure, dosage, and pain status 
may all influence whether a given exposure leads to neurotoxicity (Soriano, 
2010).  However, within these categories, there are important differences 
between animals and humans to consider when extrapolating results (see review 
by Bajic & Soriano, in press).  In both rats and humans, there is a critical window 
of vulnerability during which the nervous system is particularly sensitive to 
neurotoxic insults (see review by Bajic & Soriano, in press).  In rodents, this 
window extends to postnatal week four (De Felipe, Marco, Fairén, & Jones, 
1997; Quinn, 2005; Quincy et al., 2007).  For humans, this critical period lasts 
from the final trimester of pregnancy through 2 years of age (Huttenlocher, 1979).  
Given this difference in critical periods, it can be difficult to translate neurotoxic 
exposure in rodent models to humans.  Furthermore, analgesic dosage 
requirements in rat models (5-10 mg/kg) are much higher than in humans (0.1 
mg/kg): as much as 100 times greater.  Pain also can impact the extrapolation of 
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animal model results because animals in neurotoxic studies often do not undergo 
painful procedures.  Since untreated pain can have detrimental neurological 
effects (Anand et al., 1990; Bellù et al., 2010), it is an important factor to consider 
when evaluating neurotoxic sequelae.  Taken together, these limitations highlight 
the difficulties in extrapolating animal neurotoxicity studies to human infants.  
Therefore, it is essential to also consider clinical studies on the consequences of 
prolonged opioid exposure.        
 
Opioid Tolerance and Withdrawal 
Among neonates undergoing painful procedures, those receiving opioids may 
have improved outcomes compared to those not receiving opioids, but little is 
known about the long-term effects of prolonged opioid administration.  Infants 
requiring intubation and mechanical ventilation may receive opioids for a 
prolonged period of time, which is associated with the subsequent development 
of opioid tolerance and dependence (Anand et al., 2010).  Indeed, withdrawal 
syndrome (as manifestation of opioid dependence) is very prevalent among 
infants, with over 35-57% of infants in pediatric intensive care units (PICUs) 
exhibiting withdrawal symptoms (see review Anand et al., 2010).    
 
Several studies have examined the incidence of tolerance and withdrawal in 
pediatric patients.  Fernández-Carrión et al. conducted a retrospective cohort 
study of patients in a PICU who received continuous infusions of midazolam or 
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fentanyl for at least 48 hours.  Half of these patients exhibited symptoms of 
withdrawal, and when only considering patients who received five or more days 
of infusion, this figure increased to 80%.  Of patients exposed to less than five 
days of infusion, only one patient showed signs of withdrawal.  They found that a 
cumulative fentanyl dose of 0.48 mg/kg, a cumulative midazolam dose of 40 
mg/kg, and infusions for at least 5.75 days significantly contributed to whether a 
child developed tolerance (Fernández-Carrión et al., 2013).  Similarly, Bicudo, de 
Souza, Mângia, & de Carvalho (1999) studied withdrawal in a PICU where 
children were exposed to fentanyl and midazolam for at least 24 hours (1999).  
Like Fernández-Carrión et al.’s results, 50% of children showed signs of 
withdrawal (Bicudo et al., 1999).  Furthermore, Franck, Naughton, & Winter 
(2004) studied 15 children with complex congenital heart disease and/or 
respiratory failure who received opioids and benzodiazepines for at least four 
days.  Thirteen of these 15 children showed “moderate to severe withdrawal 
symptoms” (Franck et al., 2004).  Children most at risk for withdrawal had 
cumulative fentanyl dosages of 0.4-1.6 mg/kg, and more withdrawal was seen 
when fentanyl was added to the morphine treatment (Franck et al., 2004).  
Similar findings of neonatal abstinence syndrome were reported from a 
retrospective chart review of infants receiving continuous fentanyl infusions for 
sedation during extracorporeal membrane oxygenation (Arnold, Truog, Orav, 
Scavone, & Hershenson, 1990).  Over half (57%) of these neonates showed 
signs of fentanyl tolerance and withdrawal, and fentanyl doses had to increase by 
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five times to maintain the same analgesic level (Arnold et al., 1990), highlighting 
the high degree of opioid tolerance.  In addition, patients who had a dosage of 
fentanyl >1.6 mg/kg were much more likely to develop neonatal abstinence 
syndrome than those with a lower dosage (Arnold et al., 1990).  Similarly, Katz, 
Kelly, & Hsi (1994) conducted a case series to analyze withdrawal in children 
ages one week to 22 months who required mechanical ventilation and 
continuous fentanyl infusions.  All patients with an infusion duration of nine days 
or more or a fentanyl dosage of >2.5 mg/kg experienced withdrawal (Katz et al. 
1994).  Overall, these studies suggest that the duration of sedation and total 
dosage of opioids and benzodiazepines contribute to the development of 
tolerance and withdrawal in mechanically ventilated infants.  
 
 
Neurological Effects in Human Infants 
In addition to the potential for developing an opioid tolerance, infant opioid 
exposure may have serious long-term neurological effects (Ferguson, Ward, 
Paule, Hall, & Anand, 2012; de Graaf et al., 2011).  Several studies have 
analyzed the long-term consequences of neonatal opioid and/or benzodiazepine 
exposure, but there is still limited evidence of potential long-term neurologic 
sequelae.  Ferguson et al. (2012) followed children who had received morphine 
as infants 5-7 years later.  Although the children had normal intelligence and 
motor and behavioral development, they had decreased head circumference, 
decreased memory function, and atypical social skills (Ferguson et al., 2012).  
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Another study by de Graaf and colleagues (2011) evaluated children at 5 years 
of age who were ventilated as infants and randomized to morphine or placebo.  
The children were assessed in several areas, including behavior and intelligence, 
and morphine was associated with certain long-term neurological consequences.  
Compared to children who received a placebo, children receiving morphine had 
significantly impaired executive functioning on one subset of the intelligence test, 
“visual analysis” (de Graaf et al., 2011).    
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SPECIFIC AIMS/OBJECTIVES 
Previous research has established that the prolonged administration of opioids is 
associated with increased apoptosis in animal models.  In addition, such 
treatment is associated with physical and social deficits.  There is consensus that 
opioids are necessary for neonatal pain management, but their long-term 
consequences are still unknown.  Therefore, this study seeks to identify the 
population of infants that are at highest risk of potential maladaptations at the 
central nervous systems as a result of prolonged sedation with opioids.  
Identifying such infants would pave the road for future studies to elucidate the 
potential long-term sequelae of prolonged opioid treatment.  By identifying the 
group of infants that are exposed to prolonged administration of opioids, this 
research will contribute to the long-term safety of neonates receiving chronic 
opioids for sedation and pain management.  
 
We hypothesize that:  
1) Healthy infants will be at risk of developing opioid dependence  
2) The majority of patients will have other confounding factors (e.g. 
complex disease, surgeries, exposure to anesthesia) 
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METHODS 
Study Design 
The study is a retrospective chart review of full-term patients who received 
prolonged sedation with opioids and benzodiazepines at less than one year of 
age.  A retrospective analysis of patient charts from Boston Children’s Hospital 
was conducted over a period of one year (January 2014-January 2015).  
Potential subjects were identified through weekly screening of in-house patients 
as well as screening of infants with a diagnosis of pneumonia or respiratory 
distress.  Inclusion criteria were: full-term (37-42 weeks), less than one year of 
age, and sedation for at least three days.  Prolonged sedation was defined as 
three or more days of treatment, as similar durations have been associated with 
withdrawal symptoms in children (Fernández-Carrión et al., 2013; Franck et al., 
2004; Bicudo et al., 1999).  Information on duration of sedation, length of hospital 
stay, and Boston Children’s Hospital service were collected from patient charts. 
In addition, total doses of opioids and benzodiazepines were calculated from 
patient records, and information on diagnostic procedures and respiratory clinical 
management were collected from patient charts.  
  
	     18 
RESULTS 
Chart Review Results 
From January 2014-January 2015, a total of 221 patients were screened from 
several divisions of Boston Children’s Hospital: (1) Neonatal Intensive Care Unit 
(NICU), (2) Medical Surgical Intensive Care Unit (MSICU), (3) Medical Intensive 
Care Unit (MICU), and (4) Intermediate Care Program at Boston Children’s 
Hospital.  Out of the total 221 charts reviewed, 46 patients fit the criteria of being 
full-term, less than one year old, and receiving prolonged opioids and 
benzodiazepines, defined as at least three days of continuous infusion treatment.   
 
Figure 5 describes the diagnoses of these 46 patients. The largest category of 
infants receiving prolonged opioids and benzodiazepines was those diagnosed 
with congenital anomalies (35%; 16/46).  Of these patients with congenital 
anomalies, the largest group was infants with congenital diaphragmatic hernia 
(17%; 8/46), followed by infants with multiple congenital anomalies or syndromes 
(11%; 5/46).  Infants with cardiac congenital anomalies accounted for the 
remaining 7% (3/46) of the diagnoses.  Respiratory diseases composed 24% 
(11/46) of the diagnoses for these 46 patients.  These respiratory diseases 
consisted of either respiratory distress/infection (17%; 8/46) or other pulmonary 
diseases (7%; 3/46).  Neurological diseases accounted for 13% (6/46) of the 
diagnoses.  Four of these patients with neurological diseases were diagnosed 
with hypoxic ischemic encephalopathy, one was diagnosed with an anoxic brain 
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injury, and one was diagnosed with a congenital brain malformation.  Since 
primary neurologic disease can contribute to long-term sequelae, this group was 
excluded from analysis that involved sedation management.  The second-largest 
group was a combination of two to three of these categories (28%; 13/46).   
   
 
Patients with Respiratory Distress/Infection 
The infants in the respiratory distress/infection group were all full-term (37-42 
weeks) and did not have any other significant comorbidities besides the primary 
diagnosis; they did not have any confounding factors of prematurity, congenital 
disease, surgeries, or exposure to anesthesia.  Five of these patients had 
 
Figure 5: Diagnoses of Patients Receiving Prolonged Opioids and/or Benzodiazepines.  
The figure in the middle illustrates the diagnoses for the 46 infants eligible for analysis.  These 
infants were full-term, less than one year old, and exposed to prolonged sedation. The 
categories of diagnoses were congenital diseases, respiratory diseases, neurological 
diseases, and a combination of two to three of these categories.  The figure on the left 
describes the breakdown of congenital anomalies into congenital diaphragmatic hernia (CDH), 
cardiac, and multiple congenital anomalies.  The figure on the right illustrates the breakdown 
of the respiratory diagnoses into respiratory distress/infection and other pulmonary diseases. 
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respiratory distress due to respiratory syncytial virus (RSV) infection, two had 
meconium aspiration syndrome, and one was diagnosed with idiopathic alveolar 
hemorrhage.  All patients presented with some common symptoms that included 
cough, wheezing, and reduced feeding.  
 
Diagnostic Procedures 
Given their respiratory distress, patients received one or more chest x-ray to 
diagnose and/or follow the progress of the respiratory disease.  Patients’ x-rays 
tended to show bilateral lung opacities.  Additional radiological tests included 
abdominal x-rays, abdominal ultrasounds, computed tomography (CT) 
angiograms, bronchoscopies, and head ultrasounds.  Several patients also 
underwent echocardiograms to rule out cardiac causes of respiratory distress.  
While some of the echocardiograms showed minor abnormalities, they were 
consistent with pulmonary hypertension of the newborn.  For several patients, 
additional diagnostic procedures, such as electrocardiograms (ECGs) and 
electroencephalograms (EEGs), were done to rule out causes other than 
respiratory distress or infection.  None of the procedures required any sedation or 
anesthesia administration.  Results from these procedures were normal.  
 
 
Treatment and Sedation Management 
As defined by the inclusion criteria, all eight patients with respiratory 
disease/infection were intubated for at least three days while at Boston Children’s 
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Hospital.  Three patients were initially given a continuous positive pressure 
airway pressure (CPAP) trial for respiratory support.  Unfortunately, this 
management escalated to intubation when respiratory distress continued.  Six 
patients were given albuterol nebulizers to help treat their respiratory distress.  
Since pulmonary infection is a common cause of respiratory distress, all of the 
infants were started on antibiotics while waiting for blood and urine cultures.  The 
antibiotic course varied between patients, but multiple patients received more 
than one antibiotic at the time.  For sedation management, all eight patients 
received both opioids (fentanyl or morphine) and benzodiazepines (midazolam) 
for sedation.  Table 1 summarizes the profile of their sedation management.  The 
average length of inpatient stay at Boston Children’s Hospital was 10.1 days ± 
4.7 days.  There was a range of patient ages; the youngest patient was zero 
days old, and the oldest was six months old.  The average length of sedation was 
5.9 days ± 3.4 days.  The total amounts of midazolam, morphine, and fentanyl 
received per patient can be found in Table 1.  There was a large amount of 
variability in the total dosages received.  The total amount of midazolam received 
ranged from 13.2 mg-1,429.2 mg.  For patients receiving fentanyl, there was a 
range from 263.6 mcg- 2,212.6 mcg.  The four patients treated with morphine 
received a total dose ranging from 34.4 mg- 108.8 mg.   
 
The treatment location was fairly evenly distributed, with three patients treated in 
the MICU, three in the NICU, and two patients in the MSICU.  The NICU tended 
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to use fentanyl as the opioid for sedation and pain management, while the MICU 
and MSICU primarily used morphine.  After respiratory stabilization, patients 
were extubated to either bilateral positive airway pressure (BIPAP) or CPAP, and 
eventually to a nasal cannula or room air.  Three patients also received decadron 
to minimize airway edema that can be associated with prolonged intubation.  Two 
of the patients had bilateral pneumothoraces, which successfully resolved 
following chest tube placement under local anesthesia at the bedside.  
 
Clinical Outcomes 
Once stable on room air, patients were either discharged home or transferred to 
a local hospital.  Four of the eligible infants required a weaning regimen as they 
exhibited signs of withdrawal (Table 1 gray areas).  These were the same four 
infants that were intubated 6 days or longer; the three infants with the shortest 
periods of intubation (4 days or less) did not require a weaning protocol.  The 
weaning protocols were completed either at Boston Children’s Hospital or the 
patient’s local hospital; none of the infants were discharged home on a weaning 
protocol.  
 
Patients with Other Pulmonary Diseases 
Of the patients with other pulmonary diseases, two patients were diagnosed with 
persistent pulmonary hypertension and one with pulmonary hypoplasia.  All three 
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patients were admitted on the day of their birth, and they all presented with 
cyanosis and desaturations at birth.  
 
Diagnostic Procedures 
The three infants all had chest x-rays and echocardiograms, and two of the 
infants underwent ECGs.  Two of the patients also had head ultrasounds.  All 
three children had chest tubes placed at the bedside for bilateral 
pneumothoraces.  One infant also underwent a brain magnetic resonance 
imaging (MRI) and an EEG.      
 
Treatment and Sedation Management 
Table 1 also summarizes the sedation management for the other pulmonary 
diseases group.  The infants diagnosed with other pulmonary diseases had 
hospital stays ranging from 21 days to 86 days.  All infants were initially treated 
with 100% oxygen or CPAP, but when their respiratory distress persisted, they 
were intubated and sedated.  All patients were exposed to prolonged sedation, 
with the lengths of intubation ranging from 8.5 days to 42 days.  Like the infants 
with respiratory distress/infection, all patients received opioids (morphine or 
fentanyl) and benzodiazepine (midazolam) infusions. Table 1 presents the total 
doses of fentanyl, morphine, and midazolam per patient.  Two of the patients 
received dopamine and/or epinephrine to maintain mean arterial pressure, and 
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all three infants received multiple antibiotics at the same time until infection was 
ruled out.  
 
Clinical Outcomes       
All three patients required weaning protocols.  Two of the infants were 
discharged once stable on room air.  However, these two infants were both 
extubated to CPAP before transitioning to room air.  One infant was transferred 
to a local hospital on mechanical ventilation as well as a weaning protocol. 
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Table 1: Patients with Respiratory Diseases that Received Prolonged Opioid and 
Benzodiazepine Sedation.  A summary of the sedation management of the 11 patients with 
respiratory diseases that required intubation and mechanical ventilation. These infants were full-
term, less than one year old, did not have significant comorbidities and were considered 
otherwise healthy except for the primary lung disease for which they were admitted and received 
treatment.  Patients are arranged based on length of sedation, and age indicates age at 
admission. The first three patients with respiratory distress/infection did not require a weaning 
treatment, and the remaining eight patients (as indicated in gray) received six days or longer of 
sedation that was associated with development of opioid and benzodiazepine dependence and 
required a weaning treatment.  An asterisk in the “Hospital Stay” column indicates that the patient 
was transferred to another hospital for further management upon discharge from Boston 
Children’s Hospital.  
 
Respiratory Distress/Infection 
# Age Drugs Total Dose Length of 
Sedation 
Weaning Location Hospital 
Stay 
 
1 
 
0 days 
Fentanyl 263.6 mcg  
2 days 
 
N 
 
NICU 
 
5 days* Midazolam 13.2 mg 
 
2 
 
6 months 
Morphine 38.4 mg  
3 days 
 
N 
 
MSICU 
 
4 days Midazolam 39.2 mg 
 
3 
 
3 months 
Morphine 34.4 mg  
4 days 
 
N 
 
MSICU 
 
10 days Midazolam 34.4 mg 
 
4 
 
1 month 
Fentanyl 658.8 mcg  
6 days 
 
Y 
 
NICU 
 
17 days Midazolam 81.4 mg 
 
5 
 
 
8 weeks 
Morphine 107.0 mg  
6 days 
 
Y 
 
MICU 
 
10 days Midazolam 108.9 mg 
 
6 
 
5 months 
Morphine 108.8 mg  
6 days 
 
Y 
 
MICU 
 
13 days Midazolam 1,429.2 mg 
 
7 
 
5 weeks 
Morphine 92.7 mg  
7 days 
 
Y 
 
MICU 
 
7 days* Midazolam 64.6 mg 
 
8 
 
0 days 
Fentanyl 2,212.6 mcg  
13 days 
 
Y 
 
NICU 
 
15 days* Midazolam 97.4 mg 
Other Pulmonary Diseases 
 
 
1 
 
 
0 days 
Fentanyl 296.3 mcg  
8.5 days 
 
 
Y 
 
 
MSICU 
 
 
21 days 
Morphine 39.2 mg 
Midazolam 41.7 mg 
 
2 
 
0 days 
Fentanyl 11,422.5 mcg  
10 days 
 
Y 
 
NICU 
 
10 days*  Midazolam 85.0 mg 
 
3 
 
0 days 
Fentanyl 5,078.3 mcg  
42 days 
 
Y 
 
MSICU 
 
86 days Morphine 268.4 mg 
Midazolam 676.7 mg 
 
	     26 
 
Patients with Congenital Diseases 
As illustrated in Figure 5, patient with congenital anomalies comprised total of 
35% (16/46) of all the screened patients.  Figure 5 also shows the breakdown of 
diagnoses for infants with congenital diseases who were full-term, less than one 
year old, and received prolonged sedation for management of their primary 
congenital disease.  The largest proportion of the children was diagnosed with 
congenital diaphragmatic hernia (17%; 8/46).  The second largest category was 
infants who had multiple congenital diseases (11%, 5/46), including those with 
congenital syndromes such as CHARGE syndrome and VACTERL syndrome.  
Three of the children with syndromes had esophageal atresia as part of their 
syndrome.  The remaining 7% were patients with congenital heart diseases 
(3/46).  Because these infants have complex medical problems, all of the patients 
in this group underwent at least one surgery at Boston Children’s Hospital.  
Almost half of infants in this group received multiple antibiotics to treat an 
infection or until infection was ruled out.  
 
Diagnostic Procedures 
Many of the infants in the congenital diseases group underwent similar diagnostic 
procedures, including chest x-rays, echocardiograms, and ECGs.   Given these 
patients’ complex medical histories, they usually had multiple tests, with some 
patients having serial procedures.  Patients who had seizure activity received 
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EEGs, and infants on extracorporeal membrane oxygenation were required to 
undergo a brain MRI.  Head ultrasounds and abdominal x-rays were also used in 
multiple patients. 
 
Treatment and Sedation Management 
Table 2 describes the sedation management for infants diagnosed with 
congenital diseases and exposed to prolonged opioids and/or benzodiazepines.  
Because of the severity of the congenital diseases analyzed, these infants often 
must be intubated and sedated for multiple weeks or months.  Infants with 
congenital anomalies had a much longer length of sedation compared to those 
with respiratory diseases.  Table 2 presents the lengths of sedation for infants 
with congenital diseases.  Compared to infants with respiratory distress/infection 
(5.9 days ± 3.4 days), infants with congenital diaphragmatic hernia had an 
average of 59.3 days ± 31.3 days of sedation, and those with multiple anomalies 
had an average of 29.3 days ± 26.1 days of sedation.  For infants with congenital 
diaphragmatic hernia, the average length of hospital stay was 111.4 days ± 74.9 
days.  Patients with multiple congenital diseases had an average length of 
hospital stay of 104.0 days ± 45.8 days.  As several patients were still in the 
hospital, further follow-up is needed.  Like the infants in the respiratory 
distress/infection subject group, several different services at Boston Children’s 
Hospital were represented in the congenital diseases group.  
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There were only three full-term patients screened with cardiac congenital 
anomalies.  Their average length of hospital stay was 82.7 days ± 54.1 days.  
Their length of sedation ranged from 4+ 2 days to 11 days.  The patient with 4 + 
2 days of sedation received four days of sedation, was extubated, and then 
reintubated for two additional days of sedation.  However, two of these cardiac 
patients were first admitted to Boston Children’s Hospital at several months of 
age, and there is incomplete sedation information about initial outside treatments.  
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Table 2: Infants with Congenital Anomalies Receiving Prolonged Sedation.  Patients with 
congenital diseases who received prolonged sedation are arranged based on length of sedation.  
# in the column Hospital Stay indicates patient is deceased, and + indicates the patient was still 
inpatient at the time of screening.  With the exception of the first patient in the cardiac section, all 
surviving patients required weaning treatment. 
 
Congenital Diaphragmatic Hernia 
# Length of Sedation Hospital Stay Location 
 
1 
 
19.5 days 
 
20 days+ 
 
MICU 
 
2 
 
39.5 days 
 
94 days+ 
 
MSICU 
 
3 
 
44 days 
 
44 days# 
 
MSICU 
 
4 
 
52.5 days 
 
170 days+ 
 
NICU 
 
5 
 
60 days 
 
152 days 
 
MSICU 
 
6 
 
64 days 
 
91 days 
 
MSICU 
 
7 
 
68.5 days 
 
71 days# 
 
MSICU 
 
8 
 
126.5 days 
 
249 days 
 
MSICU 
Cardiac 
 
1 
 
4 + 2 days 
 
27 days 
 
Cardiology 
 
2 
 
6.5 days 
 
86 days# 
 
Cardiology 
 
3 
 
11 days 
 
135 days 
 
Cardiology 
Syndromes/Multiple 
 
1 
 
7.5 days 
 
42 days 
 
NICU 
 
2 
 
9 days 
 
81 days 
 
MSICU 
 
3 
 
19 days 
 
137 days+ 
 
MSICU 
 
4 
 
42 days 
 
158 days 
 
NICU 
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Clinical Outcomes 
Three infants, two with congenital diaphragmatic hernia and one with a cardiac 
congenital anomaly, were deceased at the time of screening.  Infants were 
discharged home on room air or transferred to local hospitals still on respiratory 
support.  However, many infants in this group also required multiple inpatient 
visits.  Except one patient with a cardiac congenital disease, all surviving children 
underwent a weaning protocol.       
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DISCUSSION 
This retrospective chart review describes the use of opioids and benzodiazepines 
for the pain management and sedation of intubated neonates.  These cases 
highlight the significant amounts of opioids and benzodiazepines that infants 
received while intubated for prolonged periods of time.  As infants’ brains are still 
developing, they are particularly susceptible to potential neurological effects of 
opioids (Anand et al., 2010).  It is also essential to understand the management 
of care of these infants and have insight into which patient groups have treatment 
associated with potential long-term sequelae.  
 
Study Limitations 
As a retrospective chart review, this study has limitations.  Without a comparison 
group, the chart review is a descriptive study.  A chart review also relies on the 
accuracy and completeness of patient records.   
 
Sedation Management 
Out of the total of 221 charts reviewed, only 46 fit the criteria of being less than 
one year old, full-term, and receiving prolonged sedation.  Of these 46 patients, 
only eight infants presented as otherwise healthy children less than one year old 
with respiratory disease requiring intubation, as they had no other significant 
comorbidities and did not require any surgeries.  The infants analyzed had some 
similar aspects of treatment, such as similar diagnostic procedures and antibiotic 
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courses, but the chart review highlighted the lack of uniformity in sedation 
treatment.  While all infants received continuous opioid infusions in addition to 
midazolam infusions, the opioid received varied, tending to depend on the 
service at Boston Children’s Hospital.  In accordance with the Boston Children’s 
Hospital Patient Care Manual (2009), sedation management with opioids and 
benzodiazepines has been done according to the recommended care approach 
(Figure 6). 
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Figure 6: Boston Children’s Hospital Postoperative Pain Management Document.  The Boston 
Children’s Hospital Patient Care Manual outlines recommendations for postoperative pain 
management.  Continuous infusions of opioids and benzodiazepines are recommended for 
prolonged sedation.     
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The pattern of withdrawal in these eight patients aligns with previous literature on 
opioid withdrawal.  Similar to previous studies (Fernández-Carrión et al., 2013; 
Franck et al., 2004, Bicudo et al., 1999; Arnold et al., 1990), our results suggest 
that infants with short-term opioid therapy do not show signs of withdrawal, while 
patients with 6 days of treatment or more did show signs of withdrawal.  
However, the studies by Fernández-Carrión et al., Franck et al., and Bicudo et al. 
included children older than one year old and did not exclude premature infants.  
Furthermore, Arnold et al.’s study excluded infants with congenital diaphragmatic 
hernia.  In contrast, we only analyzed full-term infants, and our analysis included 
infants with congenital anomalies.  Overall, short-term sedation is not associated 
with opioid and benzodiazepine tolerance and withdrawal, suggesting it is a valid 
therapy for mechanically ventilated infants.  However, since prolonged sedation 
leads to tolerance and withdrawal, more research is necessary to describe 
potential long-term sequelae.    
 
Future Studies 
This retrospective chart review suggests that even full-term, otherwise healthy 
infants are at risk for opioid and benzodiazepine dependence.  In addition, infants 
with congenital diseases have multiple weeks or even months of sedation, 
putting them at high risk for long-term neurological sequelae.  These children had 
diagnoses of congenital diaphragmatic hernia, multiple congenital 
anomalies/congenital syndromes, and congenital cardiac diseases.  This study 
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sets the foundation for future analysis by identifying the patient population most 
at risk for consequences of prolonged opioid exposure.   
 
Specifically, future research is necessary to: 
1) Identify structural and functional changes in the human neonatal brain 
in response to chronic opioid exposure  
2) Follow-up patients to identify structural and functional changes in 
developing brains in response to chronic opioid exposure 
 
Structural MRI and functional magnetic resonance imaging (fMRI) can be used to 
analyze potential structural and functional neurological changes in the developing 
infant brain.  The use of cognitive and behavioral tests can also help to determine 
the effects of opioids on neurocognitive function.  Since previous research 
indicates prolonged opioid exposure may be associated with deficits in 
intelligence subsets (de Graaf et al., 2011), measures of intelligence and school 
performance may also provide insight into long-term neurological consequences.  
By improving understanding of this topic, this research will contribute to the 
safety of neonates receiving chronic opioids.  
 
Conclusion 
This retrospective chart review shows that full-term infants less than one year old 
who received opioid or benzodiazepine treatment for 4 days or less did not 
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require weaning, while those who had treatment longer than 6 days required a 
weaning protocol.  The absence of tolerance and withdrawal with short therapy 
supports short-term opioid and benzodiazepine sedation as an effective 
treatment for intubated infants.  The lack of tolerance in this short-term treatment 
suggests that long-term effects may be less likely in this population than for 
infants receiving longer therapy.  However, infants exposed to prolonged 
sedation are at high risk for long-term sequelae, and thus, more research is 
necessary to understand the long-term effects of neonatal opioid exposure.  
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